## फा.सं. F. No.50014/03/2020-CDN भारत सरकार / Government of India रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals & Fertilizers औषध विभाग / Department of Pharmaceuticals

\*\*\*\*

Shastri Bhawan, New Delhi Dated: 14<sup>46</sup>December, 2022

## Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of November, 2022-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of November, 2022 for information.

Soft

(Shamim Uddin Ansari) Under Secretary to the Govt. of India Tel. 011-23387920

To,

- 1. All members of Council of Ministers.
- 2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
- 3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

- 1. Secretaries to the Govt. of India, All Ministries/Department.
- 2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
- 3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
- 4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
- 5. PS to Prime Minister of India, South Block, New Delhi-110004.
- 6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
- 7. Sr. PPS to Secretary (Pharma).
- 8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

### **Ministry of Chemicals & Fertilizers Department of Pharmaceuticals**

1. Important policy decisions taken and major achievements during the month of November 2022:

#### A. National Pharmaceutical Pricing Authority (NPPA):

(i) The details of price fixed in financial year are as under:

|   | Fixed Price/ Notified under<br>Revised Schedule I (NLEM<br>2015) |   | Cumulative from<br>1 <sup>st</sup> April, 2022 to 30 <sup>th</sup><br>November, 2022 |
|---|--|---|--|
| 1 | Retail Price of 'New Drug'                                       | - | 313  |

(ii) DoP notified revised Schedule-I to Drugs Prices Control Order, 2013 (DPCO 2013) based on the National List of Essential Medicines (NLEM 2022) vide S.O. No. 5249 dated 11.11.2022. The task of fixation of ceiling price of scheduled formulation as per revised Schedule -I of DPCO, 2013 (NLEM 2022) has commenced. On 25.11.2022, first tranche of draft ceiling price of 121 formulations uploaded on NPPA website.

(iii) A webinar on the topic "Tracking the drugs: Ensuring last mile availability" was held in hybrid mode on 30.11.2022, under the chairmanship of Dr. V. K. Paul, Member (Health), NITI Aayog. About 340 participants attended the Webinar from Pharma Association, Industry Representatives, Consumer Groups, related departments and Price Monitoring Resource Units of States/ UTs etc.

(iv) An interactive webinar to address the issues arising in implementation of 'IPDMS' Software was organised by NPPA on 10.11.2022. The PMRUs in the State/ UTs have actively participated in the webinar.

(v) NPPA through Price Monitoring and Resource Units (PMRUs) in the States/ UTs have conducted four (4) market availability surveys of COVID management drugs in November, 2022 to assess the availability of COVID Management Drugs in the States/ UTs. (vi) Total overcharged amount received during November, 2022 is Rs 8.78 lakh.

#### **B**. National Institutes of Pharmaceutical Education & Research (NIPERs):

NIPER Mohali, in collaboration with other NIPERs, organized the first International Conference on "Recent Trends and Future Opportunities in Pharmaceuticals (NIPER-PHARMACON 2022)" from 10th - 12111 November, 2022. It brought together leaders in diverse fields of pharmaceutical fields like - Drug discovery, drug delivery systems, active pharmaceutical ingredients, precision medicines, phytopharmaceuticals and medical devices. Dedicated start-up and industry sessions were also organized. More than 900 participants from international and national academia and industry attended the conference. Industry-NIPERs interaction at conference help to address R&D challenges related to specific stages of the innovation value chain in pharmaceutical sciences and secondly, to undertake joint/collaborative activities leading to human resource development, R&D, institutional capacity building, and entrepreneurship development. Further, the conference helped in networking and enhancing the brand NIPER.

In addition, following are the other significant events/achievement concerning NIPERS:

- Board of Governors (BoGs) of all seven NIPERs have been re-constituted on 2nd . November, 2022.
- Out of 615 Research papers published during the current financial year, 81 papers have been published in the month of November, 2022
- Out of 15 Patents filed during the current financial year, 4 patents filed in the month of November, 2022

- Out of 21 MoU signed during the current financial year, 4 MoU has been signed in the month of November, 2022.
- One day Symposium on "Recent Advances in Biorganic and Medicinal Chemistry" (RABMC) was conducted on 19th Nov, 2022 at NIPER Mohali.
- Painting Competition on theme "Communal Harmony, National Integration and Unity" was held on 22" Nov, 2022 at NIPER Mohali.
- Advanced Analytical Techniques on Basic Principles & Application for Quality Assessment of Drugs and Pharmaceuticals was started from 28th Nov, 2022 till 9th Dec, 2022.
- Symposia on advances in the Natural Products Research for the Treatment of Infectious diseases and Metabolic Disorders was Successfully conducted at Hyderabad on 18-19 Nov 2022.
- NIPER Hyderabad has published a review article titled "Immune CellCamouflaged Surface-engineered Nanotherapeutics for Cancer Management" in Acta Biomaterialia by Elseview with High Impact Factor- 10.633.
- NIPER Hyderahad has Published a review article "Multifunctional Hybrid Nanoparticles in diagnosis and therapy of Breast Cancer" in Journal of Controlled Release with high Impact factor- 11.467
- NIPER Hyderabad in collaboration with Dr. Reddy's Laboratories Ltd. Hyderahad has published a review article titled "albumin-Hitchhiking: fostering the Pharmacokinetics and, anticancer Therapeutics" in Journal of Controlled Release by Elsevier with high Impact Factor11.47.
- On 10th November 2022, NIPER-Ahmedabad organized an 'Interactive SciFinder-N Training Session' for students with the aim to train them for prior art search. Thanks to Mr. Milind Wagh (ACS International, Ltd.) for conducting an Interactive SciFinder Training Session.
- NIPER-Kolkata organized Industry Interaction 'Meeting with the team of Zydus Cadila from 25th Nov, 2022 to 26st Nov, 2022.
- On 29th Nov, 2022, NIPER-Kolkata organized National Seminar on "Skill set requirements for Start-up and Contract Research Organizations".
- NIPER-Hajipur organized national Symposium on "CURRENT STRATEGIES AND TECHNOLOGIES IN NANO-PHARMACEUTICALS DELIVERY" from 17th Nov, 2022 to 18th Nov, 2022.
- NIPER-Guwahati organized one virtual event on "Ideathon #2 (BioInnovation Challenge)" on 15th November 2022.

### C. Schemes:

### (i) Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):

| Number<br>Kendras fu | of PMBJP<br>Inctional | PMBJ<br>Value<br>Crore<br>to con<br>during | under<br>P at MRP<br>in Rs.<br>and saving<br>imon man<br>the month<br>November, | (As on 30.1 |          | Suvidha           | vember, |
|----------------------|-----------------------|--|---|-------------|----------|-------------------|---------|
|                      |                       | 2022                                       | ж.<br>Т   |             |          | November,<br>2022 |         |
| November<br>2022     | Cumulative            | Sale                                       | Saving  | Medicines   | Surgical |                   |         |
|                      | (As on<br>30.11.2022) | In Rs.<br>(Cr.)                            | In Rs.<br>(Cr.)<br>(Approx.)  |             |          | 0.94 Cr           | NIL     |
| 98                   | 8916                  | 105.17                                     |   | 1759        | 280      |                   |         |

### (ii) Status of PLI Schemes:

| S. No. | Name of Scheme  |         | Total No. of<br>Application<br>Received* | No. of<br>Applications<br>approved in the<br>month of<br>November 2022 | Total no. of<br>applications<br>approved till date |
|--------|---|---------|--|--|--|
| 1.     | Production  | Round 1 | 215                                      | 0  | 41   |
|        | Linked Incentive  |         | 24                                       | 0  | 08   |
|        | Scheme for Bulk   | Round 3 | 09                                       | 03   | 03   |
|        | Drug<br>(Last EC<br>Meeting held on<br>03.06.2022 on<br>PLI Bulk Drugs) | Total   | 248                                      | 03   | 51 (1 Applicant was<br>withdrawn)                  |
|        | Production<br>Linked Incentive  | Round 1 | 28                                       | 0  | 13   |
|        | Scheme for<br>Medical Device<br>( Last EC                               | Round 2 | 14                                       | 0  | 08   |
|        |   | Total   | 42                                       | 0  | 21   |
| 1 1    | Production Linked<br>Scheme for Pharm                                   |         | )/X                                      | N/A  | 55   |

2. Important policy matters held up on account of prolonged inter-ministerial consultations:

NIL

### 3. No. of cases of 'sanction for prosecution' pending for more than three months: NIL

# 4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:

NIL

### 5. Status of ongoing Swachhata Abhiyan (progress under Special Campaign):

During the month, activities related to furnishing of Information as per Self-Assessment Forms stipulated by DARPG have been completed and uploaded on SCDPM 2.0 Portal within the stipulated time schedule.

### 6. Status of Rationalization of Autonomous Bodies:

Completed

7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:

NIL

8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:

### (i) Department of Pharmaceuticals:

| S. No. | Name of the posts           | Sanctioned<br>Strength | In-position | Vacancy | Group |
|--------|-----------------------------|------------------------|-------------|---------|-------|
| 1      | Under Secretary             | 10                     | 9           | 1       | А     |
| 2      | Principal Private Secretary | 2                      | 0           | 2       | А     |
| 3      | Section Officer             | 16                     | 3           | 13      | В     |
|        | Total                       | 28                     | 12          | 16      |       |

### (ii) National Institute of Pharmaceutical Education & Research:

| NIPER            | Vacant Position |
|------------------|-----------------|
| NIPER- Raebareli | Director        |
| NIPER- Ahmedabad | Director        |

NIPER – Hajipur, Director - Under Suspension

### (iii) Public Sector Undertakings:

### (a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):

| S. No. | Designation            | Vacant Positions |
|--------|------------------------|------------------|
| 1      | Senior Manager         | 05               |
| 2      | Deputy General Manager | 03               |
| 3      | General Manager        | 05               |
|        | Total                  | 13               |

### (b) Hindustan Antibiotics Limited (HAL) (under strategic sale):

| S.No. | Designation | Vacant Position |  |  |
|-------|-------------|-----------------|--|--|
| 1     | CGM         | 3               |  |  |
| 2     | GM          | 3               |  |  |
| 3     | DGM         | 12              |  |  |
| 4     | Manager     | 20              |  |  |
|       | Total       | 38              |  |  |

### (c) Bengal Chemicals & Pharmaceuticals Limited (BCPL) (under strategic sale):

| S.No. | Designation     | Vacant Positions |
|-------|-----------------|------------------|
| 1     | DGM/AGM         | 3                |
| 2     | Sr. Manager     | 3                |
| 3     | DGM (Marketing) | 1                |
| 4     | DGM(Finance)    | 1                |
| 5     | HoD (QA/QC)     | 1                |
|       | Total           | 9                |

(d) Indian Drugs & Pharmaceuticals Limited (IDPL) : NIL

(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL) : NIL

9. List of cases in which ACC directions have not been complied with: NIL 10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:

| (i)   | Pending at beginning of the month | : | (3) |
|-------|-----------------------------------|---|-----|
| (ii)  | Received during the month         | : | (2) |
| (iii) | Disposed of during the month      | : | (1) |
| (iv)  | Pending at end of the month       | : | (4) |

\*\*\*\*\*